EGFR exon 21 mutation

News alerts, weekly reports and conference planners

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: C2 – Inclusion Criteria gefitinib Sensitive : C2	gefitinib Sensitive: C2 – Inclusion Criteria gefitinib Sensitive : C2
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	erlotinib + anlotinib Sensitive: C3 – Early Trials erlotinib + anlotinib Sensitive : C3	erlotinib + anlotinib Sensitive: C3 – Early Trials erlotinib + anlotinib Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
EGFR exon 21 mutation	Lung Adenocarcinoma	EGFR exon 21 mutation	Lung Adenocarcinoma	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	bevacizumab + osimertinib Resistant: C3 – Early Trials bevacizumab + osimertinib Resistant : C3	bevacizumab + osimertinib Resistant: C3 – Early Trials bevacizumab + osimertinib Resistant : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
EGFR exon 21 mutation	Lung Adenocarcinoma	EGFR exon 21 mutation	Lung Adenocarcinoma	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR exon 21 mutation	Small Cell Lung Cancer	EGFR exon 21 mutation	Small Cell Lung Cancer	gefitinib Sensitive: C4 – Case Studies gefitinib Sensitive : C4	gefitinib Sensitive: C4 – Case Studies gefitinib Sensitive : C4
EGFR exon 21 mutation	Lung Adenocarcinoma	EGFR exon 21 mutation	Lung Adenocarcinoma	dacomitinib Sensitive: C4 – Case Studies dacomitinib Sensitive : C4	dacomitinib Sensitive: C4 – Case Studies dacomitinib Sensitive : C4
EGFR exon 21 mutation	Lung Adenocarcinoma	EGFR exon 21 mutation	Lung Adenocarcinoma	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4

EGFR exon 21 mutation

Associations